Title:Drug Delivery System Approaches for Rheumatoid Arthritis Treatment: A
Review
Volume: 24
Issue: 7
Author(s): Anushka Garhwal, Priyadarshi Kendya, Sakshi Soni, Shivam Kori, Vandana Soni and Sushil Kumar Kashaw*
Affiliation:
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar (MP), India
Keywords:
Rheumatoid arthritis, TDDS, nanocarriers, conventional medication, molecular targets, novel therapeutic agents.
Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disease that has traditionally been
treated using a variety of pharmacological compounds. However, the effectiveness of these treatments
is often limited due to challenges associated with their administration. Oral and parenteral routes of
drug delivery are often restricted due to issues such as low bioavailability, rapid metabolism, poor
absorption, first-pass effect, and severe side effects. In recent years, nanocarrier-based delivery methods
have emerged as a promising alternative for overcoming these challenges. Nanocarriers, including
nanoparticles, dendrimers, micelles, nanoemulsions, and stimuli-sensitive carriers, possess unique
properties that enable efficient drug delivery and targeted therapy. Using nanocarriers makes it possible
to circumvent traditional administration routes' limitations. One of the key advantages of nanocarrier-
based delivery is the ability to overcome resistance or intolerance to traditional antirheumatic
therapies. Moreover, nanocarriers offer improved drug stability, controlled release kinetics, and enhanced
solubility, optimizing the therapeutic effect. They can also protect the encapsulated drug, prolonging
its circulation time and facilitating sustained release at the target site. This targeted delivery
approach ensures a higher concentration of the therapeutic agent at the site of inflammation, leading to
improved therapeutic outcomes. This article explores potential developments in nanotherapeutic regimens
for RA while providing a comprehensive summary of current approaches based on novel drug
delivery systems. In conclusion, nanocarrier-based drug delivery systems have emerged as a promising
solution for improving the treatment of rheumatoid arthritis. Further advancements in nanotechnology
hold promise for enhancing the efficacy and safety of RA therapies, offering new hope for patients
suffering from this debilitating disease.
